An Open-Label, Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Mirabegron (Primary)
- Indications Lower urinary tract symptoms; Overactive bladder
- Focus Pharmacokinetics
- 26 Nov 2012 New trial record